Get the Stockscreener App
22.03
5.41%
1.13
After Hours:
22.68
0.65
+2.95%
Neurogene Inc stock is traded at $22.03, with a volume of 178.18K.
It is up +5.41% in the last 24 hours and up +9.66% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$20.90
Open:
$21.24
24h Volume:
178.18K
Relative Volume:
1.08
Market Cap:
$341.24M
Revenue:
$925.00K
Net Income/Loss:
$-90.35M
P/E Ratio:
-5.1994
EPS:
-4.237
Net Cash Flow:
$-78.10M
1W Performance:
+12.97%
1M Performance:
+9.66%
6M Performance:
+26.57%
1Y Performance:
+55.14%
1-Day Range:
$20.81
$23.35
1-Week Range:
$18.23
$23.35
52-Week Range:
$6.875
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
22.03 | 323.74M | 925.00K | -90.35M | -78.10M | -4.237 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Neurogene (NASDAQ:NGNE) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Neurogene: Q4 Earnings Snapshot - theheraldreview.com
Neurogene Inc. Advances Gene Therapy for Rare Neurological Diseases with EXACT Platform and NGN-401 Clinical Development - Minichart
Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway - TipRanks
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Neurogene 10-K: Revenue $0.0M, EPS $(4.24) on $90.4M net loss - TradingView
Neurogene (NASDAQ: NGNE) details Rett gene therapy progress and cash runway - Stock Titan
Neurogene Reports Positive Interim Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome and Advances Toward Commercialization in 2026 - Minichart
William Blair reiterates Neurogene stock rating on trial progress - Investing.com
William Blair reiterates Neurogene stock rating on trial progress By Investing.com - Investing.com Australia
Leerink reiterates Neurogene stock rating on Rett syndrome progress By Investing.com - Investing.com Australia
Neurogene Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Neurogene : Corporate Presentation March 2026 - marketscreener.com
NGN-401 clinical developments and financials drive Neurogene Inc. corporate update - Traders Union
NGNE: NGN-401 advances with full trial enrollment, FDA Breakthrough status, and strong cash runway - TradingView
Neurogene (NGNE) deepens Rett gene therapy push with 2025 loss and long cash runway - Stock Titan
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates - marketscreener.com
BRIEF-Neurogene FY Operating Expenses USD 103.328 Million - TradingView
Rett syndrome gene therapy clears 50% dosing, no HLH cases yet - Stock Titan
Neurogene Inc.: Fundamental Analysis and Financial Ratings | | US64135M1053 - marketscreener.com
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference - MarketBeat
Neurogene Inc expected to post a loss of $1.19 a shareEarnings Preview - TradingView
Neurogene Inc: chief scientific officer Cobb sells $141k in stock - Investing.com
Insider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 4,045 Shares of Stock - MarketBeat
Neurogene (NASDAQ:NGNE) Insider Sells 6,797 Shares - MarketBeat
Neurogene (NGNE) CSO sells 6,797 shares under 10b5-1 plan - Stock Titan
Tax-driven share sale by Neurogene (NGNE) president and CFO disclosed - Stock Titan
Published on: 2026-03-17 03:31:12 - baoquankhu1.vn
Neurogene (NGNE) Expected to Announce Quarterly Earnings on Monday - MarketBeat
[144] Neurogene Inc. SEC Filing - Stock Titan
Latest NGNE NewsNeurogene Announces NGN-401 Gene Therapy fo... - Stock Titan
Neurogene to Participate in Stifel 2026 Virtual CNS Forum - Bluefield Daily Telegraph
Genetic-medicine firm Neurogene in Stifel 2026 virtual CNS fireside chat - Stock Titan
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
NGNE: Durable functional gains in Rett syndrome drive NGN-401's pivotal trial and commercial plans - TradingView
NGNE: NGN-401 shows durable, multi-domain gains in Rett syndrome, with pivotal data expected mid-2024 - TradingView
Gains Recap: Whats the analyst consensus on Neurogene Inc2026 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Will Neurogene Inc. stock outperform value stocksInsider Buying & Accurate Buy Signal Alerts - Naître et grandir
Aug Update: How correlated is Neurogene Inc to the S P500Chart Signals & Community Consensus Trade Alerts - baoquankhu1.vn
Layoff Watch: Is Neurogene Inc part of any major indexJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Aug Movers: Is Neurogene Inc backed by strong institutional buyingJuly 2025 Breakouts & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Macro Review: Is Neurogene Inc in a long term uptrend2025 Market WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Neurogene Inc. (NGNE) CFO sells 4,800 shares under 10b5-1 plan - Stock Titan
Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
NGNE SEC FilingsNeurogene 10-K, 10-Q, 8-K Forms - Stock Titan
Should You Buy Neurogene Inc (NGNE) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Neurogene: Stock Soars On FDA Designation For Rett Gene TherapyI'd Remain Cautious - Seeking Alpha
Canaccord Genuity Initiates Coverage of Neurogene (NGNE) with Buy Recommendation - Nasdaq
Neurogene Inc Stock (NGNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):